Brief: Revive Therapeutics Provides Update On FDA Phase 3 Clinical Trial For Bucillamine In Covid-19
26/10/2020 13:23
Oct 26 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON FDA PHASE 3
CLINICAL
TRIAL FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS - ESTIMATED OVER 200 PATIENTS WILL
HAVE
COMPLETED STUDY FOR INTERIM ANALYSIS BY END OF DEC 2020
Source text for Eikon: ID:nGNX3SL5qG
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure